Clinical Trials · NCT01257425
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 109
- Start date
- Dec 2010
- Locations
- 22 sites, Germany
- Primary endpoint
- Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).